Lexaria Bioscience Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Lexaria Bioscience kazanç ve gelirinin sırasıyla yıllık 49.1% ve 62.6% oranında artması tahmin edilirken, EPS'nin yıllık 48.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

49.1%

Kazanç büyüme oranı

48.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.7%
Gelir büyüme oranı	62.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	23 Jul 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:LEXX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
8/31/2027	4	-17	N/A	N/A	1
8/31/2026	1	-9	N/A	N/A	2
8/31/2025	1	-7	N/A	-4	3
8/31/2024	0	-5	N/A	-3	3
5/31/2024	0	-5	-5	-5	N/A
2/29/2024	0	-5	-5	-5	N/A
11/30/2023	0	-6	-6	-6	N/A
8/31/2023	0	-7	-6	-6	N/A
5/31/2023	0	-7	-6	-5	N/A
2/28/2023	0	-7	-5	-5	N/A
11/30/2022	0	-7	-5	-5	N/A
8/31/2022	0	-7	-5	-5	N/A
5/31/2022	0	-7	-5	-5	N/A
2/28/2022	0	-7	-5	-5	N/A
11/30/2021	0	-7	-5	-4	N/A
8/31/2021	1	-6	-4	-4	N/A
5/31/2021	1	-5	-4	-3	N/A
2/28/2021	1	-4	-3	-3	N/A
11/30/2020	1	-4	-3	-3	N/A
8/31/2020	0	-4	-3	-3	N/A
5/31/2020	0	-4	-3	-3	N/A
2/29/2020	0	-4	-3	-3	N/A
11/30/2019	0	-4	-4	-3	N/A
8/31/2019	0	-4	-4	-3	N/A
5/31/2019	0	-4	-4	-3	N/A
2/28/2019	0	-6	-3	-3	N/A
11/30/2018	0	-7	-3	-3	N/A
8/31/2018	0	-7	-3	-3	N/A
5/31/2018	0	-6	-2	-2	N/A
2/28/2018	0	-3	N/A	-2	N/A
11/30/2017	0	-2	N/A	-2	N/A
8/31/2017	0	-2	N/A	-2	N/A
5/31/2017	0	-1	N/A	-1	N/A
2/28/2017	0	-1	N/A	-1	N/A
11/30/2016	0	-1	N/A	-1	N/A
8/31/2016	0	-1	N/A	-1	N/A
5/31/2016	0	-1	N/A	-1	N/A
2/29/2016	0	-2	N/A	-1	N/A
11/30/2015	0	-2	N/A	-2	N/A
8/31/2015	0	-2	N/A	-2	N/A
5/31/2015	0	-2	N/A	-1	N/A
2/28/2015	0	-2	N/A	-1	N/A
11/30/2014	N/A	-2	N/A	-1	N/A
8/31/2014	N/A	-2	N/A	-1	N/A
7/31/2014	1	-1	N/A	0	N/A
4/30/2014	1	-1	N/A	0	N/A
1/31/2014	1	0	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LEXX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: LEXX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: LEXX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: LEXX şirketinin gelirinin (yıllık 62.6% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LEXX şirketinin gelirinin (yıllık 62.6% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LEXX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Lexaria Bioscience Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 24%

Consensus revenue estimates increase by 24%

Consensus revenue estimates increase by 100%

Consensus revenue estimates decrease by 20%, EPS upgraded

Consensus revenue estimates increase by 38%, EPS downgraded

Consensus revenue estimates fall by 65%

Recent updates

Lexaria Bioscience Corp. Receives Final 12-Week Body Weight and Blood Sugar Results from All 12 Study Groups of the Recently Completed Diabetes Animal Study

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Announces Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives Partial 12-Week Body Weight Results from the Recently Completed Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Begins Dosing in Human Pilot Study for Oral Tirzepatide Using Dehydratech Technology

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Lexaria Bioscience Corp. Announces Second GLP-1 Human Pilot Study Shows Zero Adverse Events in Dehydratech-Processed Rybelsus Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives 4-Week and 8-Week Blood Sugar Results from Ongoing Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. Announces Positive Results from Lexaria's Molecular Characterization Study

Consensus revenue estimates fall by 24%

Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2

Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Lexaria Bioscience Receives Nasdaq Bid Price Deficiency Notice

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

Lexaria Bioscience Corp. Announces Chief Financial Officer Changes

Lexaria Bioscience Corp. Discovers That DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

Lexaria Bioscience Corp. Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

Lexaria Bioscience Corp. Announces Batch Manufacturing of the DehydraTECH™-Processed Cannabidiol

Lexaria Bioscience Corp. has completed a Composite Units Offering in the amount of $2.0007 million.

Lexaria Bioscience Corp. has completed a Composite Units Offering.

Lexaria Bioscience Corp. Human Clinical Nicotine Study Completes Dosing as Planned

Consensus revenue estimates fall by 65%